Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma, Inc., filed a statement of changes in beneficial ownership on August 11, 2026, reporting an automatic share sale on August 10, 2026, to cover tax obligations arising from the settlement of vested restricted stock units.

Key Highlights

  • Reporting person: Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma, Inc.
  • Transaction date: August 10, 2026, involving 89 shares of common stock disposed of (transaction code S).
  • Weighted average sale price: $14.34 per share, with individual sale prices ranging from $14.27 to $14.34 per share.
  • Purpose of sale: Shares were automatically sold to cover tax withholding obligations from settlement of vested restricted stock units, according to the filing.
  • Remaining ownership: Hill directly beneficially owned 17,805 shares of common stock following the reported transaction.
  • Issuer and exchange: Lyell Immunopharma, Inc., traded on NASDAQ:LYEL.

Hill's RSU Settlement and Automatic Tax-Related Share Disposal at Lyell Immunopharma

According to the filing, Lyell Immunopharma, Inc. (NASDAQ:LYEL), a company headquartered at 201 Haskins Way, South San Francisco, California 94080, had its Chief Operating Officer, Stephen J. Hill, report a disposition of 89 shares of common stock on August 10, 2026. The filing indicates the shares were "automatically sold to cover tax withholding obligation from settlement of vested restricted stock units," meaning the sale was not a discretionary open-market transaction initiated by Hill.

The filing discloses that the weighted average price of the shares sold was $14.34, with the range of individual sale prices falling between $14.27 and $14.34 per share. The filing further notes that upon request from the SEC staff, the issuer, or a security holder of the issuer, Hill will provide full information regarding the number of shares sold at each separate price within that range. Following the transaction, the filing reports that Hill directly held 17,805 shares of Lyell Immunopharma common stock. The filing was signed by Mark Meltz as attorney-in-fact on August 11, 2026.

No derivative securities transactions were reported in Table II of this filing. The filing was submitted by one reporting person and does not indicate that it is an amendment to a prior filing. Hill's relationship to the issuer is listed solely as officer, in his capacity as Chief Operating Officer.

What Was Disclosed

The filing reported a single disposition of 89 shares of Lyell Immunopharma common stock by COO Stephen J. Hill on August 10, 2026, at a weighted average price of $14.34, automatically executed to satisfy tax withholding obligations tied to vested restricted stock unit settlement, leaving Hill with direct beneficial ownership of 17,805 shares.